Cubist’s Zerbaxa Approval Marks Firm’s Second Novel Antibiotic In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
With only two weeks left in 2014, Cubist grabs another FDA approval for an antibiotic, this time to treat Gram-negative infections.
You may also be interested in...
Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Merck Sees Decades-Long Time Horizon For Novel Antibiotics
Merck is one of the few big pharmas still investing in early-stage antibiotic R&D and is focusing long term on novel antibody and small molecule approaches, but Infectious Disease Research VP Daria Hazuda predicts the timeline for delivering innovative breakthroughs will be long.
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.